PYRAMID-ANALYTICS
16.6.2022 09:02:14 CEST | Business Wire | Press release
BIG DATA ANALYTICS CONFERENCE – Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, announced today that Tom Warren has been appointed Regional Managing Director, UK and Ireland (UKI). Warren brings with him twelve years of experience leading high achieving teams, alongside his previous experience as a professional rugby player, to build upon Pyramid’s growth in the UKI. The company’s customers in the UKI include Ann Summers, Liberty London, and Premier Foods.
The appointment follows Pyramid Analytics’ recent oversubscribed US $120MM Series E funding round, which was announced at a special event on May 9 from Tower Bridge in London. Pyramid is doubling down on its investment in the UKI, a leading market for decision intelligence adoption. In 2022, the UK tech ecosystem hit a landmark valuation of $1 trillion . At the centre of this tech success story is London. Pyramid plans to double its headcount in London over the coming months, to then use London as a base to support its European expansion. The appointment of Warren highlights Pyramid’s commitment to, and ambitions for, the UK and Ireland.
Key Points:
- Pyramid Analytics, a decision intelligence platform provider, hires experienced technology sector leader Tom Warren to accelerate UKI growth. Warren has twelve years leading successful teams and customer relationship management.
- Pyramid expanding investment in UKI talent, sales and marketing, and partner expansion.
- Warren’s appointment is the first in a series of planned business development initiatives to support customer success and strategic accounts in this region.
- Click here to schedule a demo of the Pyramid Decision Intelligence Platform .
Warren’s remit is to build out the UK and Ireland business, which will involve enterprise sales, business development, and channel and solutions engineering functions. Having started his career as a professional rugby player, Tom Warren is excited about the challenge ahead.
Meet our new Managing Director
Warren had a successful career as a professional rugby player for Worcester Warriors , London Irish , Grand Parma in Italy and finally at Esher RFC . This included a Division 1 title for Worcester in 2004 and playing in an English Premiership semi-final and European Challenge Cup final for London Irish in 2006. After his retirement, Warren initially turned his hand to coaching as the Scrum Coach and Director of the Academy at Esher.
Since then, he has had a successful career in sales. His most recent role was as Area VP Northern Europe at the cloud-based logistics platform Bringg where he was responsible for building out the EMEA sales team. In a previous role as Senior Director for EMEA Enterprise renewals at Blue Prism, he successfully increased customer renewals from 82% to 88%, which accounted for a 113% increase in the 2019 financial year. He was also Regional Sales Director at ServiceNow, where he set up the first UK Commercial sales team and consistently exceeded targets for delivering new business to help grow the UK business.
Decision Intelligence is the Next Big Data Analytics Innovation
The next major innovation in analytics is Artificial Intelligence (AI). Applying AI across Data Prep, Business Analytics, and Data Science is what separates Decision Intelligence from traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. AI lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.
The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.
Quotes
Omri Kohl, Chief Executive Officer and Co-Founder, Pyramid Analytics: “Tom has brought a vast wealth of expertise and insight to the Managing Director role. He has a strong history of leading impressively successful sales and customer relationship teams and has helped multiple companies expand their sales outreach into the EMEA region.
“As a former professional rugby player and with over twelve years of heading sales teams, we knew that Tom would bring strong leadership skills, courage and energy to our growing team here at Pyramid. We believe that Tom is the right individual to lead our already high performing team to continue our growth in the UK and Ireland, following our phenomenal Series E funding round performance.”
Tom Warren , Regional Managing Director, UKI, Pyramid Analytics : “Pyramid is what’s next in analytics and the UK is what’s next for Pyramid. I am really excited to be joining Pyramid Analytics and even more so to be joining a successful and high performing team, which has been behind their expansion in the UK and Ireland.
“Our Series E funding round earlier this month was a real statement of intent from the company, showcasing our ambition to expand our UK and Ireland operations so that Decision Intelligence can continue to transform the way businesses operate in the region. I look forward to contributing to this great company and working towards our European expansion.”
About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for everyone to make faster, more informed decisions. It provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. Decision Intelligence Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo .
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners , Jerusalem Venture Partners (JVP), Sequoia Capital , and Viola Growth . Learn more at Pyramid Analytics .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005248/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom